Proyectos
Estudios clínicos y proyectos de investigación sobre el Déficit de DAO:
2018-2019
Effect to Gastrointestinal Barrier Function During Laparoscopic Gastrectomy With Deep vs Moderate Neuromuscular Blockade.
Link to the Clinical Trial page in NIH ClinicalTrials.gov
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Collaborator: Wu Jieping Medical Foundation
Information provided by (Responsible Party): The First Affiliated Hospital with Nanjing Medical University
Brief Summary:
On the basis of moderate pneumoperitoneum pressure(10 mmHg), this study evaluates the effect of different level of neuromuscular blockade to gastrointestinal barrier function during laparoscopic gastrectomy. 60 patients are randomized to 2 arms ,The patients in deep NMB（PTC=1-2）will receive high dose rocuronium ;While the patients in moderate NMB（TOF=1-2）will receive moderate dose rocuronium.
Detailed Description:
Different level of neuromuscular blockade can affect the demand of pneumoperitoneum pressure,while high level of pneumoperitoneum pressure may cause some damage to gastrointestinal barrier which is important to the recovery of the patient. In this study,we will evaluate the effect of different level of neuromuscular blockade to the barrier by DAO and D-lactic in plasma, the microstructural changes of intestinal tract will be observed under scanning electron microscope and the recovery of intestinal function will be recorded.
Study design:
| Study Type: | Interventional (Clinical Trial) |
| Estimated Enrollment: | 60 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Effect to Gastrointestinal Barrier Function During Laparoscopic Gastrectomy With Deep vs Moderate Neuromuscular Blockade. |
| Estimated Study Start Date: | January 1, 2019 |
| Estimated Primary Completion Date: | December 31, 2019 |
| Estimated Study Completion Date: | December 31, 2019 |
2017-2019
TRATAMIENTO CON DIAMINO-OXIDASA (DAO) EN PACIENTES CON RINITIS NO ALÉRGICA: UN ENSAYO CLÍNICO ALEATORIZADO, CONTROLADO Y DOBLE CIEGO PARA COMPROBAR LA EFICACIA Y SEGURIDAD.
1.Mayo1, GN. Esquía1, MJ. Rial2
1Servicio de Otorrinolaringología.
2Servicio de Alergología.
Complexo Hospitalario Universitario A Coruña (CHUAC).
2016-2019
OBTENCIÓN DE MICROORGANISMOS PROBIÓTICOS CON ACTIVIDAD DAO ENDÓGENA.
M.Carmen Vidal Carou, Mariluz latorre, Teresa Veciana, Oriol Comas.
Institucion (UB)
Proyecto copatrocinado por DR Healthcare, incluido en la Comunidad Ris3cat de Alimentación.
Este proyecto está cofinanciado por la Unión Europea a través del Fondo Europeo de Desarrollo Regional (FEDER)
